Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Death Dis ; 5: e1445, 2014 Oct 09.
Artigo em Inglês | MEDLINE | ID: mdl-25299770

RESUMO

We sought to identify miRNAs that can efficiently induce apoptosis in ovarian cancer cells by overcoming BCL-X(L) and MCL1 anti-apoptotic activity, using combined computational and experimental approaches. We found that miR-491-5p efficiently induces apoptosis in IGROV1-R10 cells by directly inhibiting BCL-X(L) expression and by inducing BIM accumulation in its dephosphorylated form. This latter effect is due to direct targeting of epidermal growth factor receptor (EGFR) by miR-491-5p and consequent inhibition of downstream AKT and MAPK signalling pathways. Induction of apoptosis by miR-491-5p in this cell line is mimicked by a combination of EGFR inhibition together with a BH3-mimetic molecule. In contrast, SKOV3 cells treated with miR-491-5p maintain AKT and MAPK activity, do not induce BIM and do not undergo cell death despite BCL-XL and EGFR downregulation. In this cell line, sensitivity to miR-491-5p is restored by inhibition of both AKT and MAPK signalling pathways. Altogether, this work highlights the potential of miRNA functional studies to decipher cell signalling pathways or major regulatory hubs involved in cell survival to finally propose the rationale design of new strategies on the basis of pharmacological combinations.


Assuntos
Proteínas Reguladoras de Apoptose/metabolismo , Apoptose , Carcinoma/fisiopatologia , Receptores ErbB/genética , Receptores ErbB/metabolismo , Proteínas de Membrana/metabolismo , MicroRNAs/metabolismo , Neoplasias Ovarianas/fisiopatologia , Proteínas Proto-Oncogênicas/metabolismo , Proteína bcl-X/genética , Proteínas Reguladoras de Apoptose/genética , Proteína 11 Semelhante a Bcl-2 , Carcinoma/genética , Carcinoma/metabolismo , Linhagem Celular Tumoral , Regulação para Baixo , Feminino , Humanos , Proteínas de Membrana/genética , MicroRNAs/genética , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/metabolismo , Proteínas Proto-Oncogênicas/genética , Proteína bcl-X/metabolismo
2.
Int J Pharm ; 458(1): 197-207, 2013 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-24084450

RESUMO

We report the development of folate-functionalized nanoparticles able to target folate receptors, and to deliver a poorly water soluble cytotoxic agent, a tripentone, in ovarian carcinoma. The stability under incubation of lipid nanoparticles formulated by a low-energy phase inversion temperature method was investigated. Thanks to the presence of Labrasol(®), a macrogolglyceride into the composition of the nanocarriers, the conjugation of different quantities of a folate derivate (folic acid-polyethylene glycol2000-distearylphosphatidylethanolamine) to nanoparticles was possible by a rapid, soft, very simple post-insertion process. As determined by dynamic light scattering, nanoparticles present a monodisperse diameter of about 100 nm, a spherical shape as attested by transmission electron micrographs, a weakly negative surface zeta potential, and are able to encapsulate the tripentone MR22388. The presence of folate receptors on SKOV3 human ovarian cancer cells was identified by fluorescent immunocytochemistry. Cellular uptake studies assessed by flow cytometry indicated that these nanoparticles reached the SKOV3 cells rapidly, and were internalized by a folate-receptor mediated endocytosis pathway. Moreover, nanoparticles allowed the rapid delivery of the antitumor agent tripentone into cells as shown in vitro by real-time cellular activity assay. Such folate-lipid nanoparticles are a potential carrier for targeted delivery of poorly water soluble compounds into ovarian carcinoma.


Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/química , Carcinoma/tratamento farmacológico , Nanopartículas/administração & dosagem , Nanopartículas/química , Neoplasias Ovarianas/tratamento farmacológico , Linhagem Celular Tumoral , Química Farmacêutica/métodos , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos/métodos , Excipientes/administração & dosagem , Excipientes/química , Feminino , Ácido Fólico , Humanos , Lipídeos/administração & dosagem , Lipídeos/química , Tamanho da Partícula , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/química , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA